Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Viking Therapeutics reported revenue of $0 in the fiscal year ended Dec 2025. Net income was −$360M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Research & development | 45.0 | 54.2 | 63.8 | 102 | 345 |
| Operating income | −55.7 | −70.4 | −101 | −151 | −393 |
| Pre-tax income | – | – | −85.9 | −110 | −360 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | −55.0 | −68.9 | −85.9 | −110 | −360 |
| Diluted EPS | −0.71 | −0.90 | −0.91 | −1.01 | −3.19 |
| Diluted shares | 77.2 | 76.8 | 94.3 | 109 | 113 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 26.4 | 36.6 | 55.5 | 26.7 | 166 |
| Current assets | 211 | 167 | 367 | 907 | 716 |
| Total assets | 211 | 169 | 368 | 908 | 716 |
| Payables | 1.4 | 8.5 | 7.5 | 9.8 | 53.3 |
| Current liabilities | 8.8 | 21.9 | 19.1 | 27.4 | 76.7 |
| Total liabilities | 8.8 | 23.2 | 20.1 | 28.0 | 76.7 |
| Shareholders' equity | 202 | 145 | 348 | 880 | 639 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −47.6 | −48.4 | −73.4 | −87.8 | −279 |
| Stock-based compensation | 6.1 | 8.7 | 16.8 | 29.7 | 40.8 |
| Share buybacks | – | 6.8 | – | – | – |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −27.2% | −47.4% | −24.7% | −12.5% | −56.3% |
| ROCEEBIT ÷ (assets − current liabilities) | −27.6% | −48.0% | −28.9% | −17.1% | −61.5% |
| Cash conversion (CFO ÷ net income) | 0.87x | 0.70x | 0.85x | 0.80x | 0.77x |
| Current ratio | 24.0x | 7.61x | 19.2x | 33.1x | 9.33x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.